Previous studies have shown that the ability of CD34+ progenitor cells differentiate to DCs in vitro in MDS patients is relatively decreased, and the defect in the number of DC precursor cells may lead to malignant clones evades immune recognition and promoting the progression of MDS to AML [31]. This evidence concerns the gene CD34 and acute myeloid leukemia.